MX2015012970A - Formas de dosificacion solidas de liberacion prolongada antiemeticas. - Google Patents
Formas de dosificacion solidas de liberacion prolongada antiemeticas.Info
- Publication number
- MX2015012970A MX2015012970A MX2015012970A MX2015012970A MX2015012970A MX 2015012970 A MX2015012970 A MX 2015012970A MX 2015012970 A MX2015012970 A MX 2015012970A MX 2015012970 A MX2015012970 A MX 2015012970A MX 2015012970 A MX2015012970 A MX 2015012970A
- Authority
- MX
- Mexico
- Prior art keywords
- amount
- antiemetic
- drug
- dosage forms
- solid dosage
- Prior art date
Links
- 239000002111 antiemetic agent Substances 0.000 title abstract 6
- 230000003474 anti-emetic effect Effects 0.000 title 1
- 238000013265 extended release Methods 0.000 title 1
- 239000007909 solid dosage form Substances 0.000 title 1
- 239000011159 matrix material Substances 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 229920000831 ionic polymer Polymers 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describe una forma de dosificación oral sólida que incluye un núcleo que comprende una matriz polimérica no iónica, una primera cantidad de un primer fármaco antiemético o una sal farmacéuticamente aceptable del mismo dispersa dentro de la matriz, y una sal dispersa dentro de la matriz; un primer recubrimiento de sello de una matriz polimérica no iónica que rodea el núcleo; y una capa de fármaco de liberación inmediata que rodea el primer recubrimiento de sello, donde la capa de fármaco de liberación inmediata comprende un polímero no iónico y una segunda cantidad de un segundo fármaco antiemético o de una sal farmacéuticamente aceptable del mismo dispersa en el mismo, donde la capa de fármaco se diseña suficientemente para liberar la segunda cantidad de fármaco antiemético durante por lo menos 1 hora, donde la forma de dosificación oral sólida se diseña suficientemente para liberar la primera cantidad del primera fármaco antiemético y la segunda cantidad del segundo fármaco antiemético durante un período mínimo de 16 horas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361782395P | 2013-03-14 | 2013-03-14 | |
PCT/IB2014/001633 WO2014181195A2 (en) | 2013-03-14 | 2014-03-14 | Antiemetic extended release solid dosage forms |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015012970A true MX2015012970A (es) | 2016-04-11 |
Family
ID=51528070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012970A MX2015012970A (es) | 2013-03-14 | 2014-03-14 | Formas de dosificacion solidas de liberacion prolongada antiemeticas. |
Country Status (19)
Country | Link |
---|---|
US (5) | US20140271851A1 (es) |
EP (1) | EP2983664B1 (es) |
JP (1) | JP6282676B2 (es) |
KR (1) | KR102270521B1 (es) |
CN (2) | CN112274489A (es) |
AU (1) | AU2014264342B2 (es) |
BR (1) | BR112015022398B1 (es) |
CA (1) | CA2905553C (es) |
CL (1) | CL2015002666A1 (es) |
ES (1) | ES2946985T3 (es) |
HK (1) | HK1223012A1 (es) |
IL (1) | IL241580B (es) |
MX (1) | MX2015012970A (es) |
NZ (1) | NZ712159A (es) |
PH (1) | PH12015502093A1 (es) |
RU (1) | RU2679448C2 (es) |
SG (1) | SG11201507450TA (es) |
WO (2) | WO2014184662A2 (es) |
ZA (1) | ZA201506961B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201507450TA (en) | 2013-03-14 | 2015-10-29 | Redhill Biopharma Ltd | Antiemetic extended release solid dosage forms |
EP3116500B1 (en) | 2014-03-11 | 2023-09-13 | RedHill Biopharma Ltd. | Ondansetron extended release solid dosage forms for treating diarrhea predominant irritable bowel syndrome |
CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
KR102300335B1 (ko) * | 2018-10-19 | 2021-09-10 | 주식회사 삼양홀딩스 | 아프레피탄트의 경구용 조성물 |
WO2024096892A1 (en) * | 2022-11-03 | 2024-05-10 | Lumos Pharma, Inc. | Compactable oral formulations of ibutamoren |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4720353A (en) * | 1987-04-14 | 1988-01-19 | Richardson-Vicks Inc. | Stable pharmaceutical w/o emulsion composition |
US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
US6733789B1 (en) * | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
JP2003516345A (ja) | 1999-12-09 | 2003-05-13 | アルザ・コーポレーション | 抗ウイルス剤 |
WO2003024427A1 (en) | 1999-12-20 | 2003-03-27 | Temple University Of The Commonwealth System Of Higher Education | Tableted oral extended release dosage form |
US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
US20020044962A1 (en) * | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
US20020172712A1 (en) | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
GB0119012D0 (en) * | 2001-08-03 | 2001-09-26 | Strakan Group Plc | Transdermal delivery of drugs |
GB0129489D0 (en) * | 2001-12-10 | 2002-01-30 | Quadrant Healthcare Uk Ltd | Sustained-release compositions |
US20050131045A1 (en) * | 2002-04-30 | 2005-06-16 | Judith Aronhime | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them |
US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
US20040147510A1 (en) | 2003-01-13 | 2004-07-29 | Dynogen Pharmaceuticals, Inc. | Method of treating nausea, vomiting, retching or any combination thereof |
ATE552838T1 (de) | 2003-11-14 | 2012-04-15 | Senju Pharma Co | Wässrige lösung mit aminoglykosid-antibiotikum und bromfenac |
RU2382637C2 (ru) * | 2004-04-30 | 2010-02-27 | Астеллас Фарма Инк. | Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию |
CA2590802A1 (en) * | 2004-12-20 | 2006-06-29 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
WO2007073702A2 (es) * | 2005-12-29 | 2007-07-05 | Osmotica Corp. | Comprimido multicapa con combinación de triple liberación |
US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
US20080004260A1 (en) * | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
CN101484147B (zh) | 2006-08-18 | 2015-07-08 | 赢创罗姆有限责任公司 | 对于具有水中良好溶解性的活性成分具有受控的活性成分释放性的药物组合物 |
CN100584319C (zh) | 2006-10-16 | 2010-01-27 | 北京科信必成医药科技发展有限公司 | 群孔释放渗透泵控释片及其制备方法 |
CN101528205A (zh) | 2006-10-25 | 2009-09-09 | 麦克内尔-Ppc股份有限公司 | 布洛芬组合物 |
GB0624087D0 (en) | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
JP2010514679A (ja) * | 2006-12-22 | 2010-05-06 | スリーエム イノベイティブ プロパティズ カンパニー | 制御放出組成物及び方法 |
WO2009118763A1 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Multilayered pharmaceutical compositions and processes thereof |
US20100196291A1 (en) * | 2009-01-30 | 2010-08-05 | Laurence Halimi | Personal care sunscreen compositions having reduced eye irritation |
EP2403487A2 (en) * | 2009-03-04 | 2012-01-11 | Fdc Limited | Oral controlled release dosage forms for water soluble drugs |
US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
RU2427389C2 (ru) * | 2009-10-09 | 2011-08-27 | Александр Владимирович Диковский | Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей |
EP2506714A4 (en) * | 2009-11-30 | 2013-07-03 | Aptalis Pharmatech Inc | MOUTH ONDANSETRON TABLET COMPOSITIONS TO PREVENT EVIL AND CRUSH |
WO2011077451A2 (en) * | 2009-12-22 | 2011-06-30 | Abbott Healthcare Private Limited | Controlled release pharmaceutical composition |
EP2519226A1 (en) | 2009-12-28 | 2012-11-07 | MonoSol Rx, LLC | Orally administrable film dosage forms containing ondansetron |
JP2013536832A (ja) | 2010-08-30 | 2013-09-26 | ルピン・リミテッド | ミルナシプランの制御放出医薬組成物 |
US20120128730A1 (en) | 2010-11-23 | 2012-05-24 | Nipun Davar | Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron |
SG11201507450TA (en) | 2013-03-14 | 2015-10-29 | Redhill Biopharma Ltd | Antiemetic extended release solid dosage forms |
-
2014
- 2014-03-14 SG SG11201507450TA patent/SG11201507450TA/en unknown
- 2014-03-14 WO PCT/IB2014/001589 patent/WO2014184662A2/en active Application Filing
- 2014-03-14 CN CN202011222247.XA patent/CN112274489A/zh active Pending
- 2014-03-14 CN CN201480024401.9A patent/CN105530935A/zh active Pending
- 2014-03-14 NZ NZ712159A patent/NZ712159A/en not_active IP Right Cessation
- 2014-03-14 ES ES14795266T patent/ES2946985T3/es active Active
- 2014-03-14 JP JP2015562425A patent/JP6282676B2/ja active Active
- 2014-03-14 BR BR112015022398-2A patent/BR112015022398B1/pt active IP Right Grant
- 2014-03-14 WO PCT/IB2014/001633 patent/WO2014181195A2/en active Application Filing
- 2014-03-14 US US14/212,954 patent/US20140271851A1/en not_active Abandoned
- 2014-03-14 MX MX2015012970A patent/MX2015012970A/es unknown
- 2014-03-14 KR KR1020157028825A patent/KR102270521B1/ko active IP Right Grant
- 2014-03-14 CA CA2905553A patent/CA2905553C/en active Active
- 2014-03-14 AU AU2014264342A patent/AU2014264342B2/en active Active
- 2014-03-14 EP EP14795266.7A patent/EP2983664B1/en active Active
- 2014-03-14 US US14/212,694 patent/US9636305B2/en active Active
- 2014-03-14 RU RU2015143993A patent/RU2679448C2/ru active
-
2015
- 2015-09-10 IL IL241580A patent/IL241580B/en active IP Right Grant
- 2015-09-14 CL CL2015002666A patent/CL2015002666A1/es unknown
- 2015-09-14 PH PH12015502093A patent/PH12015502093A1/en unknown
- 2015-09-18 ZA ZA2015/06961A patent/ZA201506961B/en unknown
-
2016
- 2016-09-20 HK HK16111017.8A patent/HK1223012A1/zh unknown
-
2017
- 2017-03-22 US US15/466,214 patent/US20170189340A1/en not_active Abandoned
- 2017-08-16 US US15/678,386 patent/US20180028452A1/en not_active Abandoned
-
2020
- 2020-07-01 US US16/918,538 patent/US20200330392A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502093A1 (en) | Antiemetic extended release solid dosage forms | |
PH12014501446A1 (en) | Solid nicotine-comprising dosage form with reduced organoleptic disturbance | |
MX2015012589A (es) | Formulaciones farmaceuticas resistentes a la manipulacion. | |
MX347753B (es) | Formulaciones resistentes al abuso. | |
UA117685C2 (uk) | Складена композиція для перорального введення, яка містить езетиміб та розувастатин | |
UY31698A (es) | Preparacion solida de desintegracion oral | |
MX363142B (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona. | |
PH12020550806A1 (en) | Core tablet composite preparation comprising mosapride and rabeprazole | |
EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
IN2013MU03658A (es) | ||
WO2014114255A3 (zh) | 一种定位速释生物粘附剂及应用 | |
MX2012013021A (es) | Formulaciones resistentes a alcohol. | |
MX2016005477A (es) | Formas de dosificacion disuasivas del abuso. | |
BR112013000300A2 (pt) | comprimido que se desintegra intraoralmente | |
TR201001417A1 (tr) | Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu | |
PH12016501756A1 (en) | Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms | |
IN2014DN03429A (es) | ||
MX2019003039A (es) | Forma de dosificacion de alivio prolongado. | |
HRP20130082A2 (hr) | Farmaceutski pripravak za produljeno oslobađanje trimetazidina | |
MX354453B (es) | Microcapsulas de piperaquina y composiciones que las contienen. | |
BR112014026040A2 (pt) | tablete de liberação sustentada que contém levodropropizina e método para preparar o mesmo | |
ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
PH12015501534B1 (en) | Sustained release formulations of lorazepam | |
MX2012013023A (es) | Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina. | |
EP3065737A4 (en) | Oral pharmaceutical form for preventing vascular diseases, tablet as pharmaceutical form and gelatin capsule as pharmaceutical form |